Literature DB >> 12610747

Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors.

Giuseppe Zuccalà1, Graziano Onder, Claudio Pedone, Matteo Cesari, Emanuele Marzetti, Alberto Cocchi, Pierugo Carbonin, Roberto Bernabei.   

Abstract

OBJECTIVE: The objective of this study was to assess whether calcium antagonists, which have been proven to dilate the afferent glomerular arteriole, might prevent increases in serum creatinine levels among older subjects who started treatment with angiotensin-converting enzyme (ACE) inhibitors.
METHODS: We explored the association between use of calcium antagonists and incident increases in serum creatinine in 780 elderly patients with baseline creatinine levels <1.2 mg/dL (106.19 micromol/L), who were enrolled in a multicenter pharmacoepidemiology study, and who started using ACE inhibitors during their hospital stay. Among these participants, 279 also started using calcium antagonists. Demographic variables, comorbid conditions, medications, and objective tests, which were associated with increasing serum creatinine levels in separate regression models, were examined as potential confounders in a summary model.
RESULTS: Among patients receiving ACE inhibitors, serum creatinine levels increased in 22% of participants who were dispensed calcium antagonists, and in 31% of other patients (P=0.005). In the summary regression model, use of calcium antagonists was associated with a decreased risk of worsening renal function (RR 0.56, 95% CI 0.37-0.84). The adjusted risk of increasing serum creatinine was lower (RR 0.25, 95% CI 0.05-0.95) in participants receiving higher calcium antagonists dosages than in those taking lower dosages. This protective effect of calcium antagonists was not detected in patients not dispensed ACE inhibitors.
CONCLUSION: ACE inhibitors are underused in older subjects, mainly because of the higher incidence of renal damage among geriatric populations. Our results indicate that among elderly patients receiving ACE inhibitors, the use of calcium antagonists is associated with a reduced risk of worsening renal function. Thus, these results warrant trials aiming at establishing whether combined treatment with calcium antagonists might allow the use of ACE inhibitors in clinical practice to be expanded to the elderly population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610747     DOI: 10.1007/s00228-002-0555-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.

Authors:  J Zhang; K F Yu
Journal:  JAMA       Date:  1998-11-18       Impact factor: 56.272

2.  Disparate effects of calcium antagonists on renal microcirculation.

Authors:  K Hayashi; T Nagahama; K Oka; M Epstein; T Saruta
Journal:  Hypertens Res       Date:  1996-03       Impact factor: 3.872

Review 3.  The management of chronic heart failure.

Authors:  J N Cohn
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

4.  Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction.

Authors:  B A Bart; W A Gattis; S J Diem; C M O'Connor
Journal:  Am J Cardiol       Date:  1997-04-15       Impact factor: 2.778

5.  Inhibition of arterial thrombogenesis by quinapril but not losartan.

Authors:  A A Bavry; D Li; D S Zander; M I Phillips; J L Mehta
Journal:  J Cardiovasc Pharmacol Ther       Date:  2000-04       Impact factor: 2.457

6.  Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression.

Authors:  Y Ding; N D Vaziri
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

Review 7.  Combination of ACE inhibitors and calcium antagonists: a logical approach.

Authors:  F T Ruschitzka; G Noll; T F Lüscher
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

8.  Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.

Authors:  R R Bailey; B I Shand; A H Smith; R A Robson; K L Lynn
Journal:  Clin Nephrol       Date:  1997-10       Impact factor: 0.975

9.  Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction.

Authors:  J Mason; P Young; N Freemantle; R Hobbs
Journal:  BMJ       Date:  2000-11-04

10.  Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure.

Authors:  P A Kalra; M Kumwenda; P MacDowall; M O Roland
Journal:  BMJ       Date:  1999-01-23
View more
  2 in total

Review 1.  Pharmacotherapy review: angiotensin-converting enzyme inhibitors.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

Review 2.  Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker.

Authors:  Brent M Egan
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.